Navigation Links
INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA
Date:1/20/2012

BEVERLY, Mass., Jan. 20, 2012 /PRNewswire/ -- INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that the National Health Surveillance Agency (ANVISA) in Brazil has granted approval of the INVOcell for use as a Class II device. This approval allows the INVOcell to be sold to millions of infertile couples in Brazil and marks a major milestone in the history of the company.  The approval opens the door for INVO Bioscience to one of the largest markets and fastest growing economies in the world with over 190 million people. 

The approval by ANVISA follows the completion of a 40 patient clinical trial conducted in Rio de Janeiro, Brazil. The trial was sponsored and conducted by Dr. Francisco Augusto Colucci Coelho of the Center of Infertility and Fetal Medicine of North Rio de Janeiro, Brazil. The results from Dr. Coelho's trial, along with clinical trial results from Dr. Elkin Lucena of the Colombian Fertility and Sterility Center (CECOLFES) in Colombia, South America were submitted to ANVISA for the purpose of gaining registration and approval for the sale of the INVOcell device in Brazil. As originally announced on January 25, 2011, the trial was designed as a 40 patient clinical trial to establish safety, efficacy and comparative in-vitro fertilization (IVF) measures of the INVOcell device.

"Approval in Brazil is a very important step in the success of INVOcell due to the strength of support in the country by medical thought leaders such as Dr. Coelho," stated Kathleen Karloff, chief executive officer for INVO Bioscience. "Today's announcement paves the way for the more than 125 fertility centers in Brazil to begin offering infertile couples a safe and cost effective solution compared to traditional IVF.  We look forward to working with EcoMed, our distribution partner in Brazil, as they begin ramping up their sales and marketing efforts."

Ms. Karloff continued, "Ecomed, founded in 1978, has sought to provide the Brazilian medical community with the most current and innovative medical products. We believe that they have the ability to access the segment of the medical professional market that will be providing the INVOcell procedure.  If INVOcell is successful in capturing 5% of the identified marketplace, it could equate to more than $10 million in product sales. We look forward to a long and successful relationship."

The many advantages of the INVOcell device and procedure include:

  • the processing of significantly fewer eggs from patients, reducing the occurrence of multiple pregnancies and the attendant costs and complications;
  • the relative cost advantages of the INVOcell procedure compared to traditional IVF treatments;
  • pregnancy rates that are comparable to traditional IVF treatments.
  • INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. Additionally, INVOcell is available in many South American countries, has commenced registration processes in many others, and with this approval is now available for sale in Brazil.

    About INVO Bioscience

    INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

    Private Securities Litigation Reform Act of 1995

    This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.Contact: Kathleen Karloff  INVO Bioscience, Inc.  978-878-9505 ext 504 

    www.invobioscience.com


    '/>"/>
    SOURCE INVO Bioscience
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
    3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
    4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
    5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
    7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
    8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
    9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
    10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
    11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
    (Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
    (Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
    Breaking Medicine Technology:
    (Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... ... management skills and infrastructure. Most providers, however, are unsure how to move forward, ... Ascend to define a path forward tailored to an organization’s specific needs. ...
    (Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
    (Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 on ... head and neck cancer in individuals with unhealthy oral hygiene habits. The article goes ... whether they had gum disease, brushed their teeth on a daily basis, wore dentures ...
    (Date:6/23/2016)... , ... June 23, 2016 , ... ... today announced SentinelSecure™, its containerized mobile security software, is featured in the current ... online community that identifies leading companies with innovative technology solutions and features them ...
    Breaking Medicine News(10 mins):